Statement: the primary trial and the secondary trial have entirely different adverse event reports.
Primary_evidence: Adverse Events 1:   Total: 2/17 (11.76%)   Nausea * 1/17 (5.88%)   Pain - Abdomen NOS * 1/17 (5.88%)   Constipation * 1/17 (5.88%)
Secondary_evidence: Adverse Events 1:   Total: 19/51 (37.25%)   Febrile neutropenia 6/51 (11.76%)   Anaemia 1/51 (1.96%)   Leukopenia 1/51 (1.96%)   Neutropenia 1/51 (1.96%)   Thrombocytopenia 0/51 (0.00%)   Pericarditis 1/51 (1.96%)   Atrial flutter 0/51 (0.00%)   Cardiac failure congestive 0/51 (0.00%)   Visual impairment 0/51 (0.00%)   Dysphagia 1/51 (1.96%)   Abdominal pain 0/51 (0.00%)   Chills 1/51 (1.96%) Adverse Events 2:   Total: 17/50 (34.00%)   Febrile neutropenia 0/50 (0.00%)   Anaemia 1/50 (2.00%)   Leukopenia 0/50 (0.00%)   Neutropenia 1/50 (2.00%)   Thrombocytopenia 1/50 (2.00%)   Pericarditis 0/50 (0.00%)   Atrial flutter 1/50 (2.00%)   Cardiac failure congestive 1/50 (2.00%)   Visual impairment 1/50 (2.00%)   Dysphagia 0/50 (0.00%)   Abdominal pain 1/50 (2.00%)   Chills 0/50 (0.00%)